Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
| ▸ | TNF | P01375 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 7/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.37 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.37 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.37 |
| ▸ | NEK6 | Q9HC98 | 2/20 | 0.37 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.37 |
| ▸ | MAP4K3 | Q8IVH8 | 1/20 | 0.37 |
| ▸ | ROR1 | Q01973 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29686895 | 1.00 | RIPK1 (1.00) | RIPK1RIPK2RIPK3TNFABL1 | |
| SCHEMBL29353518 | 1.00 | RIPK1 (1.00) | RIPK1RIPK2RIPK3TNFABL1 | |
| SCHEMBL21678896 | 1.00 | RIPK1 (1.00) | RIPK1RIPK2RIPK3TNFABL1 | |
| SCHEMBL17471690 | 0.99 | RIPK1 (0.99) | RIPK1RIPK2RIPK3TNFABL1 | |
| SCHEMBL17471719 | 0.99 | RIPK1 (0.99) | RIPK1RIPK2RIPK3TNFABL1 | |
| SCHEMBL16084958 | 0.96 | RIPK1 (0.92) | RIPK1RIPK2RIPK3TNFABL1 | |
| SCHEMBL16084944 | 0.95 | RIPK1 (0.90) | RIPK1RIPK2RIPK3TNFABL1 | |
| SCHEMBL16084949 | 0.88 | RIPK1 (0.79) | RIPK1RIPK2RIPK3TNFABL1 | |
| SCHEMBL16084948 | 0.88 | RIPK1 (0.79) | RIPK1RIPK2RIPK3TNFABL1 | |
| SCHEMBL16084950 | 0.88 | RIPK1 (0.78) | RIPK1RIPK2RIPK3ABL1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | claimed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | claimed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | claimed |
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-117320754-A | Prostatitis treatment | 北京生命科学研究所 | 2023-12-29 | — | — | CN | disclosed |
| US-20230277538-A1 | THERAPEUTICS FOR THE TREATMENT OF FSHD | UCL BUSINESS LTD (GB) | 2023-09-07 | — | — | US | disclosed |
| US-20220288077-A1 | PROSTATITIS TREATMENT | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES (CN) | 2022-09-15 | — | — | US | disclosed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | disclosed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | disclosed |
| US-20200046714-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-13 | — | — | US | disclosed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | disclosed |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| WO-2014145022-A1 | HYBRID NECROPTOSIS INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885RIPK2 5/4885RIPK3 1/4885 |
| US-20200046714-A1 | Treating Male Senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885RIPK2 5/4885RIPK3 1/4885 |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885RIPK2 4/4885RIPK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.